Bavituximab, also TRWH-783, represents a exciting therapeutic technique targeting phosphatidylserine (PS). PS is normally an cellular lipid located within cell membranes; however, it's often displayed on the outer of tumor cells and damaged cells, acting as being an “eat me” signal for immune cells. The molecule precisely targets PS, seeking to